CytoDyn Inc. (CYDY)
OTCMKTS: CYDY · Delayed Price · USD
0.141
-0.001 (-0.35%)
Jul 26, 2024, 3:59 PM EDT - Market closed
CytoDyn Employees
CytoDyn had 12 employees as of May 31, 2023. The number of employees decreased by 11 or -47.83% compared to the previous year.
Employees
12
Change (1Y)
-11
Growth (1Y)
-47.83%
Revenue / Employee
n/a
Profits / Employee
-$4,307,500
Market Cap
149.26M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
CYDY News
- 17 days ago - CytoDyn Announces Settlement with Amarex Clinical Research LLC - GlobeNewsWire
- 4 weeks ago - CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024 - GlobeNewsWire
- 2 months ago - CytoDyn to Host Webcast to Provide Company Update - GlobeNewsWire
- 2 months ago - May 2024 Letter to Shareholders - GlobeNewsWire
- 5 months ago - CytoDyn Announces FDA Has Lifted Clinical Hold - GlobeNewsWire
- 6 months ago - CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma - GlobeNewsWire
- 6 months ago - CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO - GlobeNewsWire
- 6 months ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY) - PRNewsWire